Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity.

Cancer research - 15 Oct 2013

Pfäffle Heike N, Wang Meng, Gheorghiu Liliana, Ferraiolo Natalie, Greninger Patricia, Borgmann Kerstin, Settleman Jeffrey, Benes Cyril H, Sequist Lecia V, Zou Lee, Willers Henning

Abstract excerpt

In patients with lung cancer whose tumors harbor activating mutations in the EGF receptor (EGFR), increased responses to platinum-based chemotherapies are seen compared with wild-type cancers. However, the mechanisms underlying this association have remained elusive. Here, we describe a cellular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Endodeoxyribonucleases
Share to Exodeoxyribonucleases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fanconi Anemia

Share to Fanconi Anemia Complementation Group D2 Protein

Share to Multifunctional Enzymes

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Poly(ADP-ribose) Polymerases

Share to Rad51 Recombinase

Source

Open in PubMed Open full text

Identifiers

PMID: 23966292
DOI: 10.1158/0008-5472.CAN-13-0044
PMCID: PMC3823187

Genes

EGFR
RAD51
FANCD2
FAN1
EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23966292-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity.PMID 23966292Read ↗

Fanconi Anemia Repair Pathway Dysfunction, a Potential Therapeutic Target in Lung CancerSemantic proximity Read ↗

FANCA Deficiency Induces Oncogenic R-Loop Dependent Synthetic Lethality with PARP1 InhibitorsSemantic proximity Read ↗

Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments.Semantic proximity Read ↗

Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination RepairSemantic proximity Read ↗

Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy.Semantic proximity Read ↗

EGFR Mutations Compromise Hypoxia-Associated Radiation Resistance through Impaired Replication Fork-Associated DNA Damage Repair.Semantic proximity Read ↗

Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers.Semantic proximity Read ↗

Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials.Semantic proximity Read ↗

Erlotinib Attenuates Homologous Recombinational Repair of Chromosomal Breaks in Human Breast Cancer CellsSemantic proximity Read ↗

Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options.Semantic proximity Read ↗

VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine DemethylasesSemantic proximity Read ↗

Targeting Fanconi anemia/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.